Home Business A Boost in Minor Cannabinoids Supply in US Market: Sanobiotec Closes Deal...

A Boost in Minor Cannabinoids Supply in US Market: Sanobiotec Closes Deal with Open Book Extracts

This will present new scaling opportunities for novel cannabinoids, including CBN, CBC, THCV, and CBDV

sanobiotec (2)

Sanobiotec is partnering up with Open Book Extracts (OBX) to boost minor cannabinoid supply in the US market. Along with more prospects for research, this is a major step towards accelerating the commercialization and distribution of pure and stable cannabinoids at scale. 

Dave Neundorfer, CEO at OBX, noted OBX prides itself on identifying promising and innovative companies and partnering with them to grow and accelerate their distribution. Therefore they are pleased to partner up and look forward to increasing awareness and availability of the premium rare cannabinoids throughout the pharmaceutical, wellness, and cosmetics industries. 

OBX has a wide distribution network, including established CBD brands, CPGs, multi-state operators, manufacturers, and research laboratories. Due to innovation in both R&D and production, we are able to offer them the highest quality cannabinoids at competitive pricing while ensuring high production volume: this is key, as our goal is to support OBX in supplying the US market with a full portfolio of minor cannabinoids that are currently in great demand.

Being recognized as a leading manufacturer of minor cannabinoids continues to incite to create novel proprietary production solutions, as well as refine our product suite to better meet the market’s needs. 

It is worth noting, that expanding the supply of high-purity products will act as a stimulus for market players to explore compound applicability with greater consistency. This will further advance the understanding of cannabinoids in general, as it affirms the need for researchers’ work and creates an incentive for them to delve even deeper.

With an expert team of researchers and scientists, we aim to continue identifying most promising compounds and developing novel methods to produce them at purity and scale. Recently, our team announced the synthesis of pure and stable Tetrahydrocannabivarin (THCV), as well as refined methods to produce CBN, CBC, and CBDV at commercial scale. Our current focus is the synthesis of CBGM (Cannabigerol Monomethyl Ether), CBL (Cannabicyclol), CBT (Cannabitriol), and Cannflavin A.